Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 4 1

Status

Terminated 2Unknown 1Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 7Genitourinary 4Other hematologic neoplasm 2Lymphoid 2Gastrointestinal 2Tumor-Agnostic 1Plasma cell 1Head & Neck 1Gynecologic 1

Conditions

Prostatic Neoplasms 2Urinary Bladder Neoplasms 1Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 409pembrolizumab 331Prednisone 289enzalutamide 283Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 252Abiraterone Acetate 217Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 117Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 106cabozantinib 104atezolizumab 104Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Single Person × Genitourinary × Clear all
NCT07260435 2025-12-03

Apa/Enza-short

Erasmus Medical Center

Phase 3 Recruiting
400 enrolled
Genitourinary

Prostatic Neoplasms

NCT03921996 2023-03-09

Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer

Swiss Cancer Institute

Phase 3 Terminated
57 enrolled
Genitourinary

Prostatic Neoplasms

NCT03347045 2017-11-20

TPC-RCT

Alberta Health Services, Calgary

Phase NA Unknown
50 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT00352859 2014-12-30

Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib

Bayer

Phase 4 Terminated
2 enrolled
Genitourinary

Carcinoma, Renal Cell, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡